Not many diseases are as threatening to humanity as cancer. And yet, even with the very significant advances in medical science of the last century, the prognosis for most cancer patients remains poor. And the available treatments are often not as efficient as needed or highly toxic with poor side effect profiles. 

At immatics, we are dedicated to fight this threat. Our team consists of highly motivated and skilled physicians, biochemists and immunologists.

So far, immatics has a good track record of success: chances are good that we found a way for developing drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severe side effects than currently available treatment options. immatics has developed peptide-based active immunotherapy at unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development.

We are currently working on the development of new substances for a number of specific cancer treatments. Our most advanced product is already in Phase II clinical trials for kidney cancer and a second product targeting colorectal cancer has recently entered a large Phase I/II clinical trial. We also have preclinical leads as well as active earlier programs in several other tumor types.

To be prepared for optimally continuing the fight against cancer, we want to grow further. To support this growth, we are seeking employees, capital and partners – people and institutions willing to join our fight.